ADI-925

N/A

Report date: 2022/11/01 16:51:27

Base Information

Drug NameADI-925
Drug Alias NameChimeric Adapter (CAd) γδ1 T cell product ADI-925ADI-925
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionAnti-MICAAnti-MICB
TargetsMHC class I polypeptide-related sequence AMHC class I polypeptide-related sequence B
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAdicet Bio Inc
China Registration ClassN/A

Develop Information

Active CompaniesAdicet Bio Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A